Literature DB >> 15546219

Targeted molecular imaging agents for cellular-scale bimodal imaging.

H Charles Manning1, Timothy Goebel, Reid C Thompson, Ronald R Price, Haakil Lee, Darryl J Bornhop.   

Abstract

Molecular imaging is a powerful tool that has the ability to elucidate biochemical mechanisms and signal the early onset of disease. Overexpression of the peripheral benzodiazepine receptor (PBR) has been observed in a variety disease states, including glioblastoma, breast cancer, and Alzheimer's disease. Thus, the PBR could be an attractive target for molecular imaging. In this paper, the authors report cellular uptake and multimodal (MRI and fluorescence) imaging of PBR-overexpressing C6 glioblastoma (brain cancer) cells using a cocktail administration approach and a new PBR targeted lanthanide chelate molecular imaging agent.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15546219     DOI: 10.1021/bc049904q

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  20 in total

Review 1.  Lanthanide probes for bioresponsive imaging.

Authors:  Marie C Heffern; Lauren M Matosziuk; Thomas J Meade
Journal:  Chem Rev       Date:  2013-12-13       Impact factor: 60.622

2.  New structure-activity relationships of N-acetamide substituted pyrazolopyrimidines as pharmacological ligands of TSPO.

Authors:  Jun Li; Michael L Schulte; Michael L Nickels; H Charles Manning
Journal:  Bioorg Med Chem Lett       Date:  2016-06-16       Impact factor: 2.823

3.  New fluorescent probes targeting the mitochondrial-located translocator protein 18 kDa (TSPO) as activated microglia imaging agents.

Authors:  Nunzio Denora; Valentino Laquintana; Adriana Trapani; Hiromi Suzuki; Makoto Sawada; Giuseppe Trapani
Journal:  Pharm Res       Date:  2011-08-05       Impact factor: 4.200

Review 4.  Application of metal coordination chemistry to explore and manipulate cell biology.

Authors:  Kathryn L Haas; Katherine J Franz
Journal:  Chem Rev       Date:  2009-10       Impact factor: 60.622

5.  Molecular imaging of the translocator protein (TSPO) in a pre-clinical model of breast cancer.

Authors:  Shelby K Wyatt; H Charles Manning; Mingfeng Bai; Stephanie N Bailey; Pascal Gallant; Guobin Ma; Laura McIntosh; Darryl J Bornhop
Journal:  Mol Imaging Biol       Date:  2009-12-01       Impact factor: 3.488

6.  Preclinical imaging evaluation of novel TSPO-PET ligand 2-(5,7-Diethyl-2-(4-(2-[(18)F]fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide ([ (18)F]VUIIS1008) in glioma.

Authors:  Dewei Tang; Michael L Nickels; M Noor Tantawy; Jason R Buck; H Charles Manning
Journal:  Mol Imaging Biol       Date:  2014-12       Impact factor: 3.488

7.  Microwave-assisted Organic Synthesis of a High-affinity Pyrazolo-pyrimidinyl TSPO Ligand.

Authors:  Dewei Tang; Jason R Buck; Matthew R Hight; H Charles Manning
Journal:  Tetrahedron Lett       Date:  2010-09-01       Impact factor: 2.415

8.  TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions.

Authors:  Allison S Cohen; Jun Li; Matthew R Hight; Eliot McKinley; Allie Fu; Adria Payne; Yang Liu; Dawei Zhang; Qing Xie; Mingfeng Bai; Gregory D Ayers; Mohammed Noor Tantawy; Jarrod A Smith; Frank Revetta; M Kay Washington; Chanjuan Shi; Nipun Merchant; H Charles Manning
Journal:  Clin Cancer Res       Date:  2020-09-15       Impact factor: 12.531

9.  Synthesis and structure-activity relationships of 5,6,7-substituted pyrazolopyrimidines: discovery of a novel TSPO PET ligand for cancer imaging.

Authors:  Dewei Tang; Eliot T McKinley; Matthew R Hight; Md Imam Uddin; Joel M Harp; Allie Fu; Michael L Nickels; Jason R Buck; H Charles Manning
Journal:  J Med Chem       Date:  2013-04-03       Impact factor: 7.446

10.  Luminescent terbium protein labels for time-resolved microscopy and screening.

Authors:  Harsha E Rajapakse; D Rajasekhar Reddy; Shabnam Mohandessi; Nathaniel G Butlin; Lawrence W Miller
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.